These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28339163)

  • 1. Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
    Scott SN; Ostrovnaya I; Lin CM; Bouvier N; Bochner BH; Iyer G; Solit D; Berger MF; Lin O
    Cancer Cytopathol; 2017 Jun; 125(6):416-426. PubMed ID: 28339163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
    Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.
    Dugas SG; Müller DC; Le Magnen C; Federer-Gsponer J; Seifert HH; Ruiz C; Savic Prince S; Vlajnic T; Zellweger T; Mertz KD; Bacon JVW; Wyatt AW; Rentsch CA; Bubendorf L
    Cancer Cytopathol; 2019 Sep; 127(9):578-585. PubMed ID: 31386310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
    Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM
    Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
    Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
    Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
    Pierconti F; Martini M; Fiorentino V; Cenci T; Capodimonti S; Straccia P; Sacco E; Pugliese D; Cindolo L; Larocca LM; Bassi PF
    Urol Oncol; 2021 Feb; 39(2):131.e17-131.e21. PubMed ID: 32773233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?
    Calò B; Sanguedolce F; Falagario UG; Chirico M; Fortunato F; Carvalho-Diaz E; Busetto GM; Bettocchi C; Carrieri G; Cormio L
    World J Urol; 2021 Oct; 39(10):3815-3821. PubMed ID: 33830306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
    Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
    World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
    Nickerson ML; Dancik GM; Im KM; Edwards MG; Turan S; Brown J; Ruiz-Rodriguez C; Owens C; Costello JC; Guo G; Tsang SX; Li Y; Zhou Q; Cai Z; Moore LE; Lucia MS; Dean M; Theodorescu D
    Clin Cancer Res; 2014 Sep; 20(18):4935-48. PubMed ID: 25225064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
    Musangile FY; Matsuzaki I; Iwamoto R; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Kojima F; Hara I; Murata SI
    Mod Pathol; 2023 May; 36(5):100120. PubMed ID: 36812689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
    Haase RN; Harving N
    Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
    Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
    BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
    Savic S; Zlobec I; Thalmann GN; Engeler D; Schmauss M; Lehmann K; Mattarelli G; Eichenberger T; Dalquen P; Spieler P; Schoenegg R; Gasser TC; Sulser T; Forster T; Zellweger T; Casella R; Bubendorf L
    Int J Cancer; 2009 Jun; 124(12):2899-904. PubMed ID: 19230026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.
    Gupta M; Milbar N; Tema G; Pederzoli F; Chappidi M; Kates M; VandenBussche CJ; Bivalacqua TJ
    World J Urol; 2019 Oct; 37(10):2051-2058. PubMed ID: 30671639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment.
    Nurminen P; Ettala O; Seppänen M; Taimen P; Boström PJ; Kaipia A
    BJU Int; 2019 Feb; 123(2):246-251. PubMed ID: 29959824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.